Arizona study committee adopts recommendations to treat obesity as chronic disease, eyes advisory council; officials flag GLP-1 costs

At a meeting of the Arizona Legislature's Obesity Treatment Study Committee, members voted to adopt a set of recommendations that would recognize obesity as a chronic disease and ask the legislature and state agencies to create an advisory council to analyze data and recommend policy and funding strategies.

The recommendations, approved by voice vote, also urge continued and expanded prevention efforts such as nutrition education and physical-activity programming and call for improved coordination among agencies and managed-care organizations.

The committee heard three presentations that informed the vote. Yamini Sobeysen, associate chief medical officer at Mercy Care, described obesity as "a growing public health issue with serious health and economic impacts," summarized treatment options and trade-offs, and cautioned that many obesity medications have only been studied for short periods. "These medicines have only been studied for short periods," she said, noting uncertainties about long-term safety and possible risks including nutrient deficiencies and changes in mood.

Steven Berg, legislative specialist for Access, reviewed data the agency provided to the Joint Legislative Budget Committee and gave estimates of current drug spending and the potential effect of newly announced negotiated pricing. Berg said Access is currently spending about $73,000,000 in total funds, including roughly $13,000,000 from the state general fund, on GLP-1 medications at current utilization and prices. "Given the new negotiated pricing of $245 per month, that number will drop down to $28,000,000 total fund and $5,000,000 general fund," he said, adding that federal matching (FMAP) and other cost-share details remain unsettled.

Committee members pressed officials on several open questions: how much of the long-term benefit will accrue to members who often churn on and off Medicaid; whether federal cost-sharing arrangements will change the state's general-fund exposure; and how adherence rates and short treatment durations affect actuarial estimates. Berg confirmed that GLP-1 prescriptions currently require prior authorization under Arizona Medicaid and agreed to provide additional utilization and adherence data.

Paul Shannon, benefits director for the Arizona Department of Administration, provided plan-level cost figures for state employees: about $23,700 annually for members listed as diabetics, $11,800 for prediabetics, $16,600 for members with obesity and an average adult plan cost of $9,265. Shannon cautioned that those categories overlap and the figures are not adjusted to remove comorbidity overlap.

Committee discussion focused on next steps and implementation: members asked that the advisory council analyze historical claims and utilization data, estimate potential cost savings from preventive care and treatment, recommend consistent treatment models across managed-care organizations, and consider equity issues for rural and tribal communities where access and nutrition options may be limited. Members also noted that some federal prevention grants and programs (for example, SNAP-Ed funding) have been reduced, a factor that could limit state capacity for prevention unless new resources are found.

A committee member moved to adopt the package "as distributed with the revisions as noted," and the motion carried on a voice vote; no roll-call tally was recorded. Committee staff said the recommendations will be offered to a sponsor for possible legislation in the next session and that departments will continue to supply data to the advisory process.

What happens next: the committee's recommendations are intended as guidance for a legislative sponsor who could introduce a bill when the new session begins; staff and the proposed advisory council will be expected to develop the details of membership, meeting cadence and specific data requests.